Warfarin is widely prescribed for patients with atrial fibrillation. In addition to unexpected bleeding, allergic skin reaction is one of its uncommon adverse effects. We herein report an 89-year-old man who, after taking warfarin for 4 years, suffered extensive skin eruptions. The skin biopsy disclosed leukocytoclastic vasculitis. The causal relationship between skin lesions and warfarin was confirmed after re-challenge of warfarin. A literature review revealed only 13 such cases reported from 1980 to 2011. Clinicians should be aware of this potential adverse effect of warfarin.
Introduction
Oral anticoagulants are widely used in the prevention and treatment of venous and arterial thrombotic events. The vitamin K antagonist, warfarin sodium, has been the most extensively used anticoagulant despite its relatively unpredictable response, narrow therapeutic index, and drug interactions. Bleeding is the major adverse effect of warfarin therapy, but other non-hemorrhagic adverse reactions are also considerable (1) . Warfarin-induced skin changes are relatively uncommon adverse effects of warfarin therapy. The cutaneous complications of warfarin therapy include ecchymosis and purpura due to an excessive anticoagulant effect, photosensitivity, maculopapular vesicular urticarial eruptions, purple toes syndrome, skin tissue necrosis, and vasculitis (2) . Warfarin-induced leukocytoclastic vasculitis (LCV) has been rarely reported and its causal relationship is warranted to be elucidated. Herein, we present the case of an 89-year-old Taiwanese man with warfarin-induced LCV, and review the previous cases with similar cutaneous manifestations.
Case Report
An 89-year-old man was admitted with a 10-day history of progressive, well-demarcated non-pruritic cutaneous lesions on his trunk and four limbs, which were reddish to violet in color and 5-10 mm in size. The lesions spread rapidly from his legs to torso and upper extremities, and only the face, neck, and chest wall were spared. He had a history of hypertension, coronary artery disease, chronic atrial fibrillation, and chronic systolic heart failure. He had prescriptions of carvedilol, losartan, diltiazem, digoxin and isosorbide dinitrate. Moreover, he had taken warfarin for 4 years due to the chronic atrial fibrillation. The patient denied a history of drug or food allergy, and denied exposure to new laundry detergent, insect bites, poison ivy or oak.
Physical examination revealed bilateral basal rales, positive hepatojugular reflux, and lower leg pitting edema. Laboratory studies revealed a hemoglobin of 10.4 g/dL; white blood cell count, 9.02×10 3 /mm 3 (1% eosinophils); platelet count, 209×10 3 /mm 3 ; creatinine, 1.42 mg/dL; erythrocyte sedimentation rate (ESR), 48 mm/hr; and normal levels of liver enzymes. The international normalized ratio (INR) was 1.42 on admission. Total eosinophil count and total IgE were normal. Testing for antistreptolysin-O, antinu- 
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clear, and anti-neutrophil cytoplasmic antibodies, syphilis, rheumatoid factor, cryoglobulins, human immunodeficiency virus, and hepatitis B and C viruses were all negative. Results of assays of coagulation function were normal (factor VIII assay, 206%; von Willebrand factor quantitation, 185%; ristocetin cofactor activity, 100%; platelet function closure time, normal). In addition, deterioration of renal function and overt proteinuria were also observed at admission. Subsequent work-up for acute kidney injury revealed a fractional excretion of sodium of 1.83%, and fractional excretion of urea nitrogen of 60.2%. Urine culture was sterile, and renal ultrasound showed no evidence of obstructive uropathy. Testing for anti-glomerular basement membrane antibodies was negative, and complement 3 level was only mildly decreased. Histological examination of the involved skin demonstrated vascular changes of small vessel walls with perivascular polymorphonuclear leukocytes and mononuclear cell infiltration, suggesting LCV (Fig. 1) . Warfarin was suspected as the cause of the vasculitis, and it was discontinued. Oral prednisone therapy was started at a dose of 40 mg/day, as well as antihistamine. The skin lesions gradually improved after the discontinuation of warfarin and initiation of steroid therapy. Furthermore, his renal function recovered, as well as proteinuria. Because the skin lesions had resolved, we reintroduced warfarin for chronic atrial fibrillation, but the skin lesions reappeared the following day. Thus warfarin was discontinued, and colchicine (0.5 mg/day) was given as recommended by an immunologist. The skin lesions were gradually resolved over the next week, and the dose of prednisone was tapered to 10 mg/day.
The patient was discharged in stable condition free of cutaneous lesions and with recovered renal function. As a substitution for warfarin, he was placed on antiplatelet agents.
Review of the literature
A literature review was performed with PubMed using the keywords "warfarin", "coumarin", "vasculitis" and "leukocytoclastic vasculitis". During the PubMed search, we found that acenocoumarol, an oral anticoagulant of the coumarin family, has also been associated with cases of vasculitis (5, 7, 8, 11) . Thus, we added "acenocoumarol" as a keyword in the literature search as well.
Ten reports were identified in the English-language literature from the years 1980 to 2011 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . From the reports we collected the following data: patient age at onset, cutaneous manifestations, latency (from initiation of treatment to onset of skin manifestations), treatment strategies for vasculitis, concomitant medications, and outcome. A summary of the reported cases is presented in Table 1 .
In addition to the present patient, there were only 13 patients (5 males and 8 females) with warfarin-induced LCV reported in the English literature, including 1 man who developed concomitant allergic interstitial nephritis (12), which was confirmed by kidney biopsy. Including the present patient, the mean age of onset was 59.5 years. The mean and median intervals from the initiation of warfarin treatment to symptom onset were 3 years (1,084 days) and 2 months (60 days), respectively. The present patient was the oldest age (89 years), and he was above the mean latency among the 14 cases. Of the 14 patients, half of the cases (7 patients) were receiving digoxin, and 4 were receiving digoxin and furosemide in addition to warfarin. Half of the patients (7/ 14) developed proteinuria and hematuria along the presence of vasculitis. In 5 of the 14 patients, repeat administration of warfarin caused recurrence of the lesions. It is noteworthy that there were 2 patients in whom warfarin was restarted (with either a lower dosage or restarted more than 1 year later) without recurrence of the vasculitis. Other than the 2 patients who died from the disease and its comorbidities, all of the other patients survived with resolution of the skin lesions after prompt management.
Discussion
In this report we presented the first Chinese case of warfarin-related LCV. LCV is a histopathologic term commonly used to denote a small-vessel vasculitis, which was diagnosed based on clinical presentation, serology, and pathohistology. The diagnostic criteria include: 1) age >16 years; 2) medications taken at disease onset; 3) palpable purura; 4) maculopapular rash; and 5) biopsy with granulocytes in a perivascular or extravascular location. The diagnosis based on the presence of 3 out of 5 criteria has 71% sensitivity and 84% specificity (21) . The common histologic features of LCV include: vascular changes with neutrophil infiltration; nuclear fragments secondary to karyorrhexis; immunoglobulin or complement deposition on direct immunofluoscence; perivascular hemorrhage and fibrinoid deposits. In the present case, the histological finding of the involved skin demonstrated superficial dermis small vascular structure changes with perivascular neutrophils and mononuclear cells infiltration. The above finding was compatible with LCV in histology. Most of the other cases presented with "fibrinoid necrosis of dermal small vessel walls, surrounded by polymorphonuclear leukocytes". Three cases demonstrated immunoglobulin or complement deposition in the vessel walls. In 2 cases skin biopsy was not performed, and their diagnosis for warfarin-induced vasculitis was only made base on only the clinical findings. All of the cases were compatible with the diagnostic criteria of LCV clinically or histologically.
Cutaneous vasculitis can be associated with infection (15-20%), inflammatory disease (15-20%), malignancy (<5%), or it can be idiopathic (45-55%) (14) . Drugs seldom cause cutaneous or systemic vasculitis, and the typical manifesta- tion is cutaneous small-vessel vasculitis (15) . Drugs are implicated in 10% to 24% of the cases with cutaneous manifestations of LCV (16) , which usually occur with a long latent period (15) . In the literature review, the interval between the first exposure to warfarin therapy and the symptoms of vasculitis was markedly varied (from days to years). Vasculitis may occur after dose titration or after re-exposure of the causative agent (17). In most of the cases, the vasculitis resolved after discontinuation of the drug.
In the present case although the relationship between warfarin therapy and the skin manifestations was not clear (due to the long latency), we believe that the vasculitis was related to warfarin because the skin lesions were resolved only after the withdrawal of warfarin, and they recurred after reexposure to warfarin. No other etiology could be identified despite an extensive work-up. In accordance with the data, and based on the algorithm of Naranjo et al (13) , an adverse reaction to warfarin is considered probable.
Warfarin-induced LCV has been reported to be associated with skin necrosis and as a distinct entity (10) , which may be accompanied by pre-existing protein C and protein S deficiency and it is typically observed 3 to 8 days after the ini-tiation of therapy. It is characterized by well-demarcated erythematous lesions, which may progress to bullae formation, and eventually to full-thickness skin necrosis (18) . Warfarin-induced LCV typically develops in a longer-term treatment, and the disease spectrum ranges from relatively benign cutaneous symptoms requiring only discontinuation of warfarin and supportive care, to a life-threatening condition requiring intensive care. Pharmacological treatments include topical and systemic corticosteroids, antihistamines, nonsteroidal anti-inflammatory drugs and immunosupressants (9). Patients with severe or life-threatening manifestations have required treatment with corticosteroids (or even pulse corticosteroids), hemodialysis, cyclophosphamide, or plasmapheresis (17). Based on our literature review, death occurred in 14.3% (2/14) of warfarin-induced LCV cases, which is compatible with the mortality rate (about 10%) in all published drug-induced vasculitis cases (17).
Of the 14 cases identified in the literature review, 7 patients were receiving digoxin and 4 digoxin and furosemide in addition to warfarin. These are common medical regimens in patients with chronic atrial fibrillation and chronic heart failure. Although digoxin and furosemide do not have clinically significant drug interactions with warfarin, digoxin may cause gastrointestinal adverse effects, including loss of appetite, nausea, vomiting and diarrhea, which may interfere with the absorption of vitamin K (19) , and may theoretically increase the efficacy of warfarin. Furosemide may prevent warfarin from binding to plasma proteins (mainly albumin) and therefore increase its availability and anticoagulant effect. A dose-dependency of drug-induced vasculitis has been suggested in some case reports (4) . From this point of view, the concomitant use of a medication with a potential drug interaction with warfarin might increase the risk of warfarininduced vasculitis in certain susceptible patients.
In the literature review, 50% of the patients were reported to have proteinuria and hematuria accompanying the vasculitis, which might be a result of drug-induced allergic (acute) interstitial nephritis. Previous case reports have demonstrated warfarin-induced allergic interstitial nephritis (20) , and the possibility of concomitant LCV and allergic interstitial nephritis (12), which were proven by tissue biopsies. In the present case, progressive worsening of renal function and overt proteinuria were observed during hospitalization, despite adequate management of blood pressure and fluid status. The nephrotic range proteinuria (maximal urine protein/creatinine ratio: 3.61) may presumably reflect cytokineinduced injury to the glomeruli. The proteinuria as well as the renal function was improved only after systemic corticosteroid therapy. Based on the aforementioned arguments, although a kidney biopsy was not obtained we concluded that this patient most likely had warfarin-induced allergic interstitial nephritis.
The latent period of LCV following administration of a causative agent has been shown to be highly variable from the literature review; as short as 3 days or as long as 12 years. The present patient had begun warfarin therapy 4 years before occurrence of the vasculitis, which is within the time frame for the development of LCV. The onset of druginduced LCV typically occurs 7 to 10 days after contact with the antigen responsible for the reaction. We can separate the 14 cases into 2 groups according to the interval between first exposure to warfarin and the appearance of the symptoms. The patients with symptom onset within 6 weeks are named "normal latency LCV", and the patients with latency of more than 6 weeks are called "late-onset LCV". Among the patients with late-onset LCV, they seemed to have a much higher prevalence of proteinuria. About 87.5% (7/8) of late-onset LCV patients developed proteinuria, and 0% of normal latency LCV patients were reported to have proteinuria. There was no significant difference in the histological findings between the normal-latency group and the late-onset group.
In summary, warfarin or other coumarin drug-induced vasculitis is very rare. To our knowledge, this is the oldest and the first case report of warfarin-induced LCV in an ethnic Chinese patient. In addition, the patient had a latent onset of LCV and presented with proteinuria in addition to skin lesions, which reappeared after re-challenging warfarin. It is critical to be aware of this potential adverse effect of warfarin to enable prompt diagnosis and treatment in similar cases.
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